4.30Open4.30Pre Close0 Volume4 Open Interest16.00Strike Price0.00Turnover153.53%IV-4.37%PremiumJan 17, 2025Expiry Date4.79Intrinsic Value100Multiplier14DDays to Expiry0.00Extrinsic Value100Contract SizeAmericanOptions Type-0.8499Delta0.0704Gamma2.24Leverage Ratio-0.0265Theta-0.0044Rho-1.91Eff Leverage0.0051Vega
Omeros Stock Discussion
how long will the hold off volume before reaching above 30
Omeros’ Narsoplimab Meets its Pivotal Trial Primary Endpoint – Statistical Analysis Shows Survival Superiority Over External Control in Patients with TA-TMA
Omeros (OMER) announced successful results from its narsoplimab pivotal trial for treating transplant-associated thrombotic microangiopathy (TA-TMA). The primary statistical analysis showed that patients treated with narsoplimab had an over 3-fold reduction in mortality risk (hazard ratio = 0.32) compared to untreated p...
No comment yet